Context: Effects of irradiation on thyroid diseases such as thyroid nodules and autoimmune thyroid diseases have not been evaluated among people exposed to radiation more than 50 years in the past.

Objective: To evaluate the prevalence of thyroid diseases and their radiation-dose responses in atomic bomb survivors.

Design, Setting, And Participants: Survey study comprising 4091 cohort members (mean age, 70 [SD, 9] years; 1352 men and 2739 women) who participated in the thyroid study at the Radiation Effects Research Foundation. Thyroid examinations were conducted between March 2000 and February 2003.

Main Outcome Measures: Prevalence of thyroid diseases, including thyroid nodules (malignant and benign) and autoimmune thyroid diseases, and the dose-response relationship of atomic bomb radiation in each thyroid disease.

Results: Thyroid diseases were identified in 1833 (44.8%) of the total participants (436 men [32.2% of men] and 1397 women [51.0% of women]) (P<.001). In 3185 participants, excluding persons exposed in utero, not in the city at the time of the atomic bombings, or with unknown radiation dose, the prevalence of all solid nodules, malignant tumors, benign nodules, and cysts was 14.6%, 2.2%, 4.9%, and 7.7%, respectively. The prevalence of positive thyroid antibodies, antithyroid antibody-positive hypothyroidism, and Graves disease was 28.2%, 3.2%, and 1.2%, respectively. A significant linear dose-response relationship was observed for the prevalence of all solid nodules, malignant tumors, benign nodules, and cysts (P<.001). We estimate that about 28% of all solid nodules, 37% of malignant tumors, 31% of benign nodules, and 25% of cysts are associated with radiation exposure at a mean and median thyroid radiation dose of 0.449 Sv and 0.087 Sv, respectively. No significant dose-response relationship was observed for positive antithyroid antibodies (P = .20), antithyroid antibody-positive hypothyroidism (P = .92), or Graves disease (P = .10).

Conclusions: A significant linear radiation dose response for thyroid nodules, including malignant tumors and benign nodules, exists in atomic bomb survivors. However, there is no significant dose response for autoimmune thyroid diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.295.9.1011DOI Listing

Publication Analysis

Top Keywords

thyroid diseases
28
thyroid
13
thyroid nodules
12
autoimmune thyroid
12
atomic bomb
12
nodules autoimmune
8
prevalence thyroid
8
diseases
7
radiation
5
radiation dose-response
4

Similar Publications

This review focuses on the latest advancements in using biomarkers to diagnose, predict outcomes, and guide the treatment of different types of thyroid cancer, such as anaplastic, papillary, medullary, and follicular thyroid carcinoma. We highlight the key role of both traditional and new biomarkers in improving the treatment of these cancers. For anaplastic thyroid cancer, biomarkers are crucial for detecting distant metastases and making treatment decisions.

View Article and Find Full Text PDF

Whether autoimmune diseases caused any effects on the risk of cancers remained yet clarified. This study aimed to investigate the causal effect of autoimmune diseases on pan-cancers through mendelian randomization (MR) analysis. The GWAS summary datasets of 10 autoimmune diseases were derived from the IEU or UK biobank website.

View Article and Find Full Text PDF

BRAF-activated ARSI suppressed EREG-mediated ferroptosis to promote BRAF (mutant) papillary thyroid carcinoma progression and sorafenib resistance.

Int J Biol Sci

January 2025

Department of Thyroid and Hernia Surgery, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou City, Fujian Province 350001, China.

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer, and patients with the BRAF mutation often exhibit aggressive tumor behavior. Here, we identified Arylsulfatase I (ARSI) as a gene whose expression was significantly upregulated in BRAF PTC and was associated with poor prognosis. High ARSI expression correlated with advanced disease stage, BRAF mutation, and worse overall survival in PTC patients.

View Article and Find Full Text PDF

Impaired sensitivity to thyroid hormone is associated with developing non-alcoholic fatty liver disease in euthyroid diabetic subjects.

Front Endocrinol (Lausanne)

January 2025

Department of Endocrinology and Metabolism, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital, The Affiliated Hospital to Nanjing University Medical School, Nanjing, China.

Background And Aims: Acquired resistance to thyroid hormone appears to exist in the general population. We aimed to evaluate the association between indices of thyroid hormone sensitivity and non-alcoholic fatty liver disease (NAFLD), and made stratified analyses by diabetic status.

Methods: We included 26,413 participants from a health screening program and 8,246 hospitalized patients with type 2 diabetes.

View Article and Find Full Text PDF

Objectives: This study aimed to examine the publication rates of abstracts related to oculoplastic surgery and orbital diseases presented at the Turkish Ophthalmological Association National Congresses (TOA-NCs) in 2013-2022.

Materials And Methods: The study included abstracts in the field of oculoplastic surgery and orbital diseases accepted for presentation at TOA-NCs between 2013 and 2022. These abstracts were reviewed in terms of presentation type (oral, poster), number of authors, study setting (university, training and research, private, public, or abroad hospital), study type (case, clinical, or basic science), study topic (eyelid, lacrimal system, orbit, or thyroid eye disease), journal publication status, time to publication (months), publishing journal (national, international), and journal impact factor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!